Clozapine, Mortality, and Self-Harm in Treatment-Resistant Schizophrenia
New evidence bolsters the reputation of clozapine as the “gold-standard” antipsychotic for patients with treatment-resistant schizophrenia.
8 Reasons a Psychotropic Medication May Be Discontinued
Tips for having a balanced and comprehensive risk-to-benefit discussion with competent patients who want to stop their medications.
A New Drug in Development for Negative Symptoms
Is an effective, well-tolerated treatment for the negative symptoms of schizophrenia on the horizon?
The Astonishing Non-Epidemic Continues--With a Red Flag on the Field
No, there is no generalized epidemic of mental illness in the US, nor credible evidence that psychiatric drugs are driving up rates or severity of mental illness. But there is an urgent need for more and better treatment of psychiatric disorders.
Recognizing Tardive Dyskinesia: A 3-Question Quiz
What factors come into play in the diagnosis of tardive dyskinesia? How is TD distinguished from other movement disorders? Find out more in this quiz.
Off-Label Prescribing of Antipsychotics for Youths: Who Should Be Treated?
This article focuses on appropriate versus inappropriate use of antipsychotics, the importance of careful assessment, and the consequences of not treating.
Expert Q&A: Schizophrenia and Weight Gain
Schizophrenia and T2 DM risk; short-term weight gain with specific antipsychotics; interventions to reduce weight and/or metabolic abnormalities. . .answers here.
By clicking Accept, you agree to become a member of the UBM Medica Community.